Hosted on MSN

U of A's SEAR program getting ready for new school year

U of A's SEAR program getting ready for new school year NOAA’s new hurricane forecast was just released Man randomly sucker punches woman outside of Little Havana restaurant Please stop adding this ...
ESPN

Miami lands four-star athlete A'mir Sears for 2027 class

Four-star athlete A'mir Sears, ESPN's top uncommitted prospect in the 2027 cycle, gave his pledge to Miami on Friday, landing as the top-ranked member of coach Mario Cristobal's latest recruiting ...
Bleacher Report

5-Star Athlete A'Mir Sears Announces CFB Commitment Between Miami, LSU, Michigan, OSU and More

Two-way star A'Mir Sears, a 5-star prospect in the high school class of 2027, has chosen to play college football at the University of Miami. Sears announced his decision live Friday on the CBS Sports ...
WRIC

Winsome Earle-Sears hits campaign trail against proposed amendments on abortion, same-sex marriage

RICHMOND, Va. (WRIC) — Winsome Earle-Sears is returning to the campaign trail with a tour against proposed constitutional amendments that protect abortion access and same-sex marriage in Virginia ...
Hosted on MSN

Sear and cook the ultimate sous vide steak

BBQ pitmaster and founder of Meat Church BBQ Matt Pittman demonstrates how to properly prepare, season, and reverse sear a thick-cut steak using the sous vide method for perfect edge-to-edge doneness ...
Newsweek

Mark Sears is Making a Case to Get More Minutes with the Nuggets

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Mark Sears is making sure the Nuggets have a reason to keep believing ...
Seeking Alpha

Sino Biopharma receives Chinese rights to two GSK respiratory drugs

A unit of Sino Biopharmaceutical (SBMFF) has obtained commercialization rights to market two GSK (GSK)-owned respiratory drugs in mainland China, the Hong Kong-listed drugmaker announced on Wednesday.
pharmaphorum

AZ pays $200m upfront for Sino Bio COPD drug

In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic obstructive pulmonary disease (COPD) from Sino Bio for up to $2.1 billion.
Morningstar%2c Inc.

Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens Partnership With GSK — Update

Sino Biopharmaceutical has struck a licensing deal with AstraZeneca for a chronic respiratory disease treatment and obtained commercialization rights for two GSK treatments in China, as global ...
Wall Street Journal

Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens GSK Partnership

Sino Biopharm 1177-0.99%decrease; down pointing triangle aceutical has struck a licensing deal with AstraZeneca AZN-0.05%decrease; down pointing triangle for a chronic respiratory disease treatment ...
FierceBiotech

AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic obstructive pulmonary disease (COPD) drug Ohtuvayre. The deal, ...
Reuters

Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

July 8 (Reuters) - Hong Kong-listed drugmaker Sino Biopharmaceutical (1177.HK), opens new tab said on Wednesday its China unit had secured rights to ‌market two respiratory drugs from British company ...